Veloxis Pharmaceuticals Releases Annual Report for 2018
COPENHAGEN, Denmark, /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today releases its Annual Report for the financial year 2018.
A complete copy of Veloxis's Annual Report for 2018 can be accessed in the Download Center on the Company's website: http://ir.veloxis.com/download-center.
Veloxis's Executive Management will host a conference call to discuss the 2018 financial results on Thursday, February 28, 2019 at 4:00 p.m. CET (Denmark); 3:00 p.m. GST (London); and 10:00 a.m. EST (New York).
To access the live conference call, please dial one of the following numbers:
+45 32 72 75 18 (Denmark)
Confirmation Code: 2466359
Following the conference call, a recording will be available on the Company's website: http://www.veloxis.com/.
About Veloxis Pharmaceuticals
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. For further information, please visit www.veloxis.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-releases-annual-report-for-2018-300803479.html
SOURCE Veloxis Pharmaceuticals A/S
Company Codes: Copenhagen:VELO, OTC-PINK:VXPZY